Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1870 1
1916 1
1921 3
1922 4
1931 1
1932 1
1933 2
1935 1
1936 1
1937 1
1939 1
1940 1
1941 1
1942 2
1943 1
1945 2
1946 2
1947 5
1948 3
1949 2
1951 3
1952 3
1953 8
1954 6
1955 4
1956 5
1957 5
1958 5
1959 6
1960 3
1961 13
1962 10
1963 7
1964 17
1965 33
1966 41
1967 48
1968 61
1969 87
1970 83
1971 113
1972 158
1973 156
1974 189
1975 649
1976 771
1977 867
1978 831
1979 943
1980 926
1981 882
1982 972
1983 1122
1984 1071
1985 1065
1986 1038
1987 1039
1988 1116
1989 1169
1990 1093
1991 1038
1992 1081
1993 1111
1994 1020
1995 1029
1996 1194
1997 1098
1998 1150
1999 1227
2000 1360
2001 1397
2002 1465
2003 1563
2004 1594
2005 1715
2006 1873
2007 1960
2008 2152
2009 2182
2010 2339
2011 2549
2012 2758
2013 2617
2014 2798
2015 3189
2016 3175
2017 3444
2018 3830
2019 4353
2020 4728
2021 5082
2022 5263
2023 5095
2024 1568

Text availability

Article attribute

Article type

Publication date

Search Results

88,857 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: Genevi, A8ve, 20Billaud
Page 1
Did you mean geneva%C3%A8ve%20Billaud (120 results)?
C3-dependent effector functions of complement.
Zarantonello A, Revel M, Grunenwald A, Roumenina LT. Zarantonello A, et al. Immunol Rev. 2023 Jan;313(1):120-138. doi: 10.1111/imr.13147. Epub 2022 Oct 22. Immunol Rev. 2023. PMID: 36271889 Free PMC article. Review.
We will introduce the C3 forms (native C3, C3 [H(2) O], and intracellular C3), the C3 fragments C3a, C3b, iC3b, and C3dg/C3d, and the C3 expression sites. To highlight the important role that C3 plays in human biological processes, …
We will introduce the C3 forms (native C3, C3 [H(2) O], and intracellular C3), the C3 fragments C3a, C3b, …
A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Schena FP, Esposito P, Rossini M. Schena FP, et al. Int J Mol Sci. 2020 Jan 14;21(2):525. doi: 10.3390/ijms21020525. Int J Mol Sci. 2020. PMID: 31947692 Free PMC article. Review.
In April 2012, a group of nephrologists organized a consensus conference in Cambridge (UK) on type II membranoproliferative glomerulonephritis and decided to use a new terminology, "C3 glomerulopathy" (C3 GP). Further knowledge on the complement system and on kidney …
In April 2012, a group of nephrologists organized a consensus conference in Cambridge (UK) on type II membranoproliferative glomerulonephrit …
C3 Glomerulopathy.
Riedl M, Thorner P, Licht C. Riedl M, et al. Pediatr Nephrol. 2017 Jan;32(1):43-57. doi: 10.1007/s00467-015-3310-4. Epub 2016 Apr 7. Pediatr Nephrol. 2017. PMID: 27056062 Review.
In C3G, loss of AP regulation leads to predominant glomerular C3 deposition, which distinguishes C3G from IC-GN with predominant immunoglobulin G staining. ...Mutations or autoantibodies affecting the function of AP activators or regulators, in particular the decay of the …
In C3G, loss of AP regulation leads to predominant glomerular C3 deposition, which distinguishes C3G from IC-GN with predominant immu …
With complements: C3 inhibition in the clinic.
Kolev M, Barbour T, Baver S, Francois C, Deschatelets P. Kolev M, et al. Immunol Rev. 2023 Jan;313(1):358-375. doi: 10.1111/imr.13138. Epub 2022 Sep 25. Immunol Rev. 2023. PMID: 36161656 Review.
C3 is a key complement protein, located at the nexus of all complement activation pathways. ...In this review, we compare the MoA of pegcetacoplan and eculizumab in paroxysmal nocturnal hemoglobinuria and discuss the complement-mediated disease that might be amenable to
C3 is a key complement protein, located at the nexus of all complement activation pathways. ...In this review, we compare the MoA of
Emerging opportunities for C3 inhibition in the eye.
Kim BJ, Liu T, Mastellos DC, Lambris JD. Kim BJ, et al. Semin Immunol. 2022 Jan;59:101633. doi: 10.1016/j.smim.2022.101633. Epub 2022 Jul 2. Semin Immunol. 2022. PMID: 35787973 Review.
This article will discuss the location of C3 expression in the eye as well as the preclinical and clinical data regarding C3's functions in AMD. We will provide a comprehensive review of developing C3 inhibitors for the eye, including the Phase 2 and 3 data f …
This article will discuss the location of C3 expression in the eye as well as the preclinical and clinical data regarding C3's …
C3 deficiencies.
Bitter-Suermann D, Burger R. Bitter-Suermann D, et al. Curr Top Microbiol Immunol. 1990;153:223-33. doi: 10.1007/978-3-642-74977-3_12. Curr Top Microbiol Immunol. 1990. PMID: 2404696 Review. No abstract available.
Microbiome induced complement synthesized in the gut protects against enteric infections.
Wu M, Zheng W, Song X, Bao B, Wang Y, Ramanan D, Yang D, Liu R, Macbeth JC, Do EA, Andrade WA, Yang T, Cho HS, Gazzaniga FS, Ilves M, Coronado D, Thompson C, Hang S, Chiu IM, Moffitt JR, Hsiao A, Mekalanos JJ, Benoist C, Kasper DL. Wu M, et al. bioRxiv [Preprint]. 2023 Feb 3:2023.02.02.523770. doi: 10.1101/2023.02.02.523770. bioRxiv. 2023. PMID: 36778396 Free PMC article. Preprint.
C. rodentium is remarkably more invasive to the gut epithelium of C3-deficient mice than of wild-type mice. In the gut, C3-mediated phagocytosis of C. rodentium functions to clear pathogens. ...C. rodentium is significantly more invasive of the gut epithelium in …
C. rodentium is remarkably more invasive to the gut epithelium of C3-deficient mice than of wild-type mice. In the gut, C3-med …
Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases.
Meuleman MS, Grunenwald A, Chauvet S. Meuleman MS, et al. Semin Immunol. 2022 Mar;60:101634. doi: 10.1016/j.smim.2022.101634. Epub 2022 Jul 8. Semin Immunol. 2022. PMID: 35817659 Review.
C3 glomerulopathy (C3G) is a rare and complex kidney disease that primarily affects young adults. ...However, the lack of sufficient efficiency in anti-C5 therapy highlights the extreme complexity of the disease and the need for new therapeutic approaches based on C3
C3 glomerulopathy (C3G) is a rare and complex kidney disease that primarily affects young adults. ...However, the lack of sufficient
Detection of Anti-C3b Autoantibodies by ELISA.
Radanova M, Roumenina LT, Vasilev V. Radanova M, et al. Methods Mol Biol. 2021;2227:133-139. doi: 10.1007/978-1-0716-1016-9_13. Methods Mol Biol. 2021. PMID: 33847938
Autoantibodies against complement proteins are involved in the pathological process of many diseases, including lupus nephritis, C3 glomerulopathies, and atypical hemolytic uremic syndrome. This method describes the detection of autoantibodies targeting the central complem …
Autoantibodies against complement proteins are involved in the pathological process of many diseases, including lupus nephritis, C3 g …
Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface.
Pisarenka S, Meyer NC, Xiao X, Goodfellow R, Nester CM, Zhang Y, Smith RJH. Pisarenka S, et al. Front Immunol. 2023 Jan 18;13:1073802. doi: 10.3389/fimmu.2022.1073802. eCollection 2022. Front Immunol. 2023. PMID: 36846022 Free PMC article.
We use an extracellular matrix substitute (MaxGel) as a base upon which we reconstitute AP C3 convertase. We validated this method using properdin and Factor H (FH) and then assessed the effects of genetic and acquired drivers of C3G on C3 convertase. RESULTS: We sh …
We use an extracellular matrix substitute (MaxGel) as a base upon which we reconstitute AP C3 convertase. We validated this method us …
88,857 results
You have reached the last available page of results. Please see the User Guide for more information.